Safety and Clinical Activity of Itolizumab in aGVHD
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, PK, PD, and clinical activity of Itolizumab in subjects
with Newly diagnosed Acute Graft Versus Host Disease(aGVHD).